Key Takeaways
- • Medical Angels appoints Michael Batko, former Startmate CEO, as venture partner to lead fundraising efforts for a $40 million dedicated venture fund.
- • Batko brings substantial track record: 8+ years backing 300+ startups with top 5% returns, previously helmed Startmate into Australia's most active seed investor with $50M+ raised and 228 first-cheque investments.
- • The $40 million fund represents a significant expansion of Batko's investing vehicle, building on his angel syndicate (Allied Venture Partners, launched Q4 2020) and prior ~$4 million semi-annual funds that delivered up to 8.9x cash-on-cash returns.
- • Appointment signals Medical Angels' strategy to deepen venture capital deployment in healthcare/medtech sector through an experienced operator with demonstrated deal sourcing and portfolio construction capabilities.
Summary
Batko's background establishes credibility for the role. As former CEO of Startmate, Australia's oldest and largest startup accelerator, he oversaw the development of a portfolio exceeding 300 alumni companies valued collectively at $4.5 billion. During his tenure at Startmate, he raised $50 million-plus and provided first-cheque capital to 228 companies, positioning Startmate as Australia's most active seed investor before his 2025 exit. His personal investment track record spans 8+ years of venture backing with top 5% returns.
Prior to the Medical Angels appointment, Batko had been exploring a dedicated fund vehicle independent of Startmate operations. In Q4 2020, he launched Allied Venture Partners, an angel syndicate enabling co-investment alongside his deal flow. His historical fund-raising cadence involved launching approximately $4 million vehicles every six months, with those funds achieving returns as high as 8.9x cash-on-cash. This performance provides a foundation for managing a significantly larger $40 million vehicle.
The $40 million fund size represents a substantial scaling of Batko's investment activity, suggesting Medical Angels has committed substantial capital to the healthcare/medtech thesis under his stewardship. The appointment leverages both his sourcing relationships within the Australian startup ecosystem and his operational experience scaling early-stage portfolio companies, two capabilities historically critical to seed-to-Series A fund success.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.